Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Arcus Biosciences, Inc.

NYSE: RCUS · Life Sciences · 5 alerts · CIK 1724521

Arcus Biosciences, Inc. stories on ALFA USA NewsRead the news →
Share price
$16.86Close, Nov 16
Market cap
$2.43B
Shares outstanding
143.99MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Arcus Biosciences, Inc. filings on SEC EDGAR ↗

8:33 AM ET 8-K
Clinical Trial Data

Arcus Biosciences Clinical Trial Data

Arcus Biosciences presented new data from its ARC-20 platform study evaluating casdatifan in various treatment lines for clear cell renal cell carcinoma (ccRCC). Key results included a 50% confirmed objective response rate (cORR) for the first-line casdatifan plus zimberelimab combination and a 14.5-month median progression-free survival for the second-line combination with cabozantinib.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.